Telix Pharmaceuticals Limited TLX
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Australia · telixpharma.com
Commercial-stage global radiopharmaceutical company advancing targeted theranostics for cancer; its commercial franchise is anchored by the PSMA prostate-cancer imaging agents Illuccix and Gozellix, with three therapeutic assets in pivotal trials. Nasdaq line is a Level II ADR (1 ADS = 1 ordinary share); primary listing ASX: TLX.
Key ratios
CashFromOperationsYoYGrowth TTM -0.91
CashFromOperationsYoYGrowth 2024 0.93
DilutedEPSYoYGrowth TTM -0.91
DilutedEPSYoYGrowth 2024 6.51
FreeCashFlowOnSale TTM -0.05
FreeCashFlowOnSale 2025 -0.05
FreeCashFlowOnSale 2024 0.04
FreeCashFlowOnSale 2023 0.02
NetIncomeMargin TTM -0.01
NetIncomeMargin 2025 -0.01
NetIncomeMargin 2024 0.07
NetIncomeMargin 2023 0.01
ReturnOnAssets TTM 0.01
ReturnOnAssets 2025 0.01
ReturnOnAssets 2024 0.06
ReturnOnAssets 2023 0.1
ReturnOnEquity TTM -0.02
ReturnOnEquity 2025 -0.02
ReturnOnEquity 2024 0.15
ReturnOnEquity 2023 0.05
TotalRevenueYoYGrowth 2025 0.56
TotalRevenueYoYGrowth 2024 0.55
TotalRevenueYoYGrowth 2023 2.05
Recent news
Telix H1 2026 Results: Investor Webcast Notification
2026-07-30 · GlobeNewswire
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
2026-07-20 · GlobeNewswire